for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Novavax, Inc.

NVAX.O

Latest Trade

133.28USD

Change

8.86(+7.12%)

Volume

10,776,342

Today's Range

125.77

 - 

140.70

52 Week Range

3.54

 - 

189.40

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
124.42
Open
126.16
Volume
10,776,342
3M AVG Volume
187.22
Today's High
140.70
Today's Low
125.77
52 Week High
189.40
52 Week Low
3.54
Shares Out (MIL)
61.28
Market Cap (MIL)
9,159.86
Forward P/E
19.60
Dividend (Yield %)
--

Next Event

Novavax Inc Annual Shareholders Meeting

Latest Developments

More

Novavax Files Prospectus Supplement Relates To Offer, Resale Of Up To 4.4 Mln Shares Of Common Stock By Selling Stockholders

Novavax Says Expect To Have Well Over A Couple Of Billion Units Of NVX-Cov2373 Capacity On Annual Basis

Novavax Reports Q2 Loss Per Share $0.30

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Novavax, Inc.

Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company's lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).

Industry

Biotechnology & Drugs

Contact Info

21 Firstfield Rd

GAITHERSBURG, MD

20878-1757

United States

+1.240.2682000

http://www.novavax.com/

Executive Leadership

James Francis Young

Independent Chairman of the Board

Stanley C. Erck

President, Chief Executive Officer, Director

John J. Trizzino

Executive Vice President, Chief Business Officer, Chief Financial Officer and Treasurer

Gregory M. Glenn

President, Research and Development

Jill Hoyt

Chief Human Resource Officer, Executive Vice President

Key Stats

2.67 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

1.1K
EPS (USD)

2017

-12.600

2018

-10.000

2019

-5.510

2020(E)

7.428
Price To Earnings (TTM)
--
Price To Sales (TTM)
507.27
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-46.24
Return on Equity (TTM)
-41.99

Latest News

Latest News

Novavax ties up with SK bioscience to boost supply of potential COVID-19 vaccine

Novavax Inc said on Thursday South Korea's SK bioscience would manufacture a component of the U.S. drug developer's experimental coronavirus vaccine in a bid to boost its supply.

Novavax to work with SK bioscience for coronavirus vaccine component

Novavax Inc said on Thursday South Korea's SK bioscience will manufacture a component of the U.S. drug developer's experimental coronavirus vaccine.

Novavax expects it can meet U.S. COVID-19 vaccine demand in 2021, executives say

Novavax Inc's manufacturing capacity is sufficient to meet the U.S. demand for COVID-19 vaccines in 2021, which it believes could be as high as 500 million to 600 million doses, company executives said on Monday.

Takeda to make Novavax's COVID-19 vaccine candidate in Japan

Takeda Pharmaceutical will manufacture and sell up to 250 million doses of Novavax Inc's COVID-19 vaccine candidate in Japan every year, the two companies said on Friday.

BRIEF-Takeda & Novavax Announce Collaboration For Novavax' COVID-19 Vaccine Candidate In Japan

* NOVAVAX AND TAKEDA ANNOUNCE COLLABORATION FOR NOVAVAX' COVID-19 VACCINE CANDIDATE IN JAPAN

Novavax signs COVID-19 vaccine supply deal with India's Serum Institute

Novavax Inc said on Wednesday it has entered a supply and license agreement with the Serum Institute of India for the development and commercialization of its COVID-19 vaccine candidate.

Novavax coronavirus vaccine induces immune response in early study, shares jump

Novavax Inc said on Tuesday its experimental COVID-19 vaccine produced high levels of antibodies against the novel coronavirus, according to initial data from a small, early-stage clinical trial, sending the company's shares up 10%.

CORRECTED-UPDATE 1-Novavax coronavirus vaccine induces immune response in small study

Novavax Inc said on Tuesday its experimental COVID-19 vaccine produced antibodies against the novel coronavirus, according to initial data from a small, early-stage clinical trial.

Novavax coronavirus vaccine induces immune response in small study

Aug 4 - Novavax Inc said on Tuesday its experimental COVID-19 vaccine produced antibodies against the novel coronavirus and appears to be safe, according to initial data from a small, early-stage clinical trial.

Exclusive: Novavax executives could get big payday even if vaccine fails

One of the leading U.S. firms developing a coronavirus vaccine, Novavax Inc <NVAX.O>, has awarded executives stock options that could pay out tens of millions of dollars even if its efforts fail.

U.S. government awards Novavax $1.6 billion for coronavirus vaccine

The U.S. government has awarded Novavax Inc $1.6 billion to cover testing and manufacturing of a potential vaccine for the novel coronavirus in the United States, with the aim of delivering 100 million doses by January.

FACTBOX-U.S. pours billions into development of coronavirus vaccines, tests

(Updates with BARDA investment in Novavax vaccine, new grants to Regeneron's and AstraZeneca's therapies, updates development stage for AstraZeneca vaccine and diagnostics table) July 7 (Reuters) - As drugmakers race to develop vaccines, tests and therapies for the novel...

BRIEF-Novavax Announces $1.6 Billion Funding From Operation Warp Speed

* NOVAVAX ANNOUNCES $1.6 BILLION FUNDING FROM OPERATION WARP SPEED

U.S. government awards Novavax $1.6 billion for coronavirus vaccine

The U.S. government has awarded Novavax Inc $1.6 billion to cover testing, commercialization and manufacturing of a potential coronavirus vaccine in the United States, with the aim of delivering 100 million doses by January 2021.

BRIEF-Novavax Inc Says On June 24, CEPI Issued Co $76.0 Million Of $145.2 Million

* NOVAVAX INC - ON JUNE 24, CEPI ISSUED CO $76.0 MILLION OF $145.2 MILLION Source text: [https://bit.ly/2Nzbz0g] Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Novavax Announces Additions To Executive Leadership

* NOVAVAX ANNOUNCES ADDITIONS TO EXECUTIVE LEADERSHIP Source text for Eikon: Further company coverage:

BRIEF-Novavax Appoints David Mott To Board Of Directors

* NOVAVAX APPOINTS BIOTECHNOLOGY VETERAN DAVID MOTT TO BOARD OF DIRECTORS

Novavax to raise $200 million through stock offering to fund COVID-19 vaccine

Novavax Inc said on Monday it would raise fresh capital through a $200 million preferred stock offering as it races to develop a vaccine for the new coronavirus, sending its shares up 10.5%.

Novavax gets U.S. defense funding for its COVID-19 vaccine

Novavax Inc said on Thursday the U.S. Department of Defense (DoD) will give the late-stage biotech company up to $60 million to fund the manufacturing of its experimental COVID-19 vaccine.

BRIEF-Novavax Awarded Department Of Defense Contract For COVID-19 Vaccine

* NOVAVAX AWARDED DEPARTMENT OF DEFENSE CONTRACT FOR COVID-19 VACCINE

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up